| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 147, Issue 11 3855-3861, Copyright © 1991 by American Association of Immunologists
ARTICLES |
S Takafuji, SC Bischoff, AL De Weck and CA Dahinden
Institute of Clinical Immunology, Inselspital, Bern, Switzerland.
Eosinophils (Eos) produce large amounts of leukotriene C4 (LTC4) and platelet-activating factor (PAF) in response to calcium ionophore. However, the capacity of naturally occurring soluble agonists to promote lipid mediator formation by Eos is largely unknown. Our previous studies on neutrophils and basophils showed that certain hematopoietic growth factors are important regulators of lipid mediator formation. We examined LTC4 production by normal human Eos from healthy donors in response to soluble agonists with or without preincubation with the cytokines IL-3 and IL-5. Among three agonists (FMLP, C5a, PAF) tested over a wide concentration range, only FMLP induced some LTC4 formation by itself in normal Eos. However, after preincubation with IL- 3 or IL-5, Eos produced detectable amounts of LTC4 in response to all three agonists. Eos primed by IL-3 or IL-5 generated at least 1 order of magnitude more LTC4 in response to FMLP as compared to C5a or PAF. FMLP-induced LTC4 production was enhanced by 26 to 635% (n = 16) and 67 to 611% (n = 12) after preincubation with IL-3 or IL-5, respectively. Priming for LTC4 production was concentration dependent occurring at IL- 3 or IL-5 concentrations of 3 to 30 ng/ml and required an optimal preincubation period of 90 min. Thus, IL-3 and IL-5 profoundly modulate the production of lipid mediators by Eos in response to the soluble agonists FMLP, C5a, and PAF. Our data further support the importance of these cytokines in inflammatory reactions involving Eos.
This article has been cited by other articles:
|
|
 |
|
  D. Ferrari, A. la Sala, E. Panther, J. Norgauer, F. Di Virgilio, and M. Idzko Activation of human eosinophils via P2 receptors: novel findings and future perspectives J. Leukoc. Biol., January 1, 2006; 79(1): 7 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Sloane, N. Tedla, M. Awoniyi, D. W. MacGlashan Jr, L. Borges, K. F. Austen, and J. P. Arm Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition Blood, November 1, 2004; 104(9): 2832 - 2839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Thomas, W. Xu, and T. T. Ardon Immobilized Lactoferrin Is a Stimulus for Eosinophil Activation J. Immunol., July 15, 2002; 169(2): 993 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Thivierge, M. Doty, J. Johnson, J. Stankova, and M. Rola-Pleszczynski IL-5 Up-Regulates Cysteinyl Leukotriene 1 Receptor Expression in HL-60 Cells Differentiated into Eosinophils J. Immunol., November 1, 2000; 165(9): 5221 - 5226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-U. Simon, M. Weber, E. Becker, Y. Zilberman, K. Blaser, and F. Levi-Schaffer Eosinophils Maintain Their Capacity to Signal and Release Eosinophil Cationic Protein Upon Repetitive Stimulation with the Same Agonist J. Immunol., October 1, 2000; 165(7): 4069 - 4075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Bates, V. L. Green, and P. J. Bertics ERK1 and ERK2 Activation by Chemotactic Factors in Human Eosinophils Is Interleukin 5-dependent and Contributes to Leukotriene C4 Biosynthesis J. Biol. Chem., April 6, 2000; 275(15): 10968 - 10975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. HOLGATE and A. P. SAMPSON Antileukotriene Therapy . Future Directions Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S147 - 153. [Full Text] [PDF]
|
|
|
|
|
|
A. Lorentz, S. Schwengberg, G. Sellge, M. P. Manns, and S. C. Bischoff Human Intestinal Mast Cells Are Capable of Producing Different Cytokine Profiles: Role of IgE Receptor Cross-Linking and IL-4 J. Immunol., January 1, 2000; 164(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P Hood, T. P Cotter, J. F Costello, and A. P Sampson Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients Thorax, December 1, 1999; 54(12): 1075 - 1082. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Jagels, P. J. Daffern, B. L. Zuraw, and T. E. Hugli Mechanisms and Regulation of Polymorphonuclear Leukocyte and Eosinophil Adherence to Human Airway Epithelial Cells Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 418 - 427. [Abstract] [Full Text]
|
|
|
|
|
|
T. Adachi, S. Stafford, S. Sur, and R. Alam A Novel Lyn-Binding Peptide Inhibitor Blocks Eosinophil Differentiation, Survival, and Airway Eosinophilic Inflammation1, 2 J. Immunol., July 15, 1999; 163(2): 939 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Cowburn, S. T. Holgate, and A. P. Sampson IL-5 Increases Expression of 5-Lipoxygenase-Activating Protein and Translocates 5-Lipoxygenase to the Nucleus in Human Blood Eosinophils J. Immunol., July 1, 1999; 163(1): 456 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Brock, J. A. Anderson, F. P. Fries, M. Peters-Golden, and P. H. S. Sporn Decreased Leukotriene C4 Synthesis Accompanies Adherence-Dependent Nuclear Import of 5-Lipoxygenase in Human Blood Eosinophils J. Immunol., February 1, 1999; 162(3): 1669 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bates, W. W. Busse, and P. J. Bertics Interleukin 5 Signals through Shc and Grb2 in Human Eosinophils Am. J. Respir. Cell Mol. Biol., January 1, 1998; 18(1): 75 - 83. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
